IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. Most people with IgA nephropathy receive care from a nephrologist, a doctor who specializes in treating people with kidney disease.
IgA nephropathy usually doesn’t cause symptoms in the early stages, so the disease can go unnoticed for years or decades. It’s sometimes suspected when routine tests reveal protein and red blood cells in your urine that can’t be seen without a microscope (microscopic hematuria). In its early stages, IgA nephropathy may have no symptoms; it can be silent for years or even decades. Once symptoms appear, the most common one is hematuria, or blood in the urine. Hematuria can be a sign of damaged glomeruli. Blood in the urine may appear during or soon after a cold, sore throat, or other respiratory infection. The amount of blood may be: visible with the naked eye. The urine may turn pink or the color of tea or cola. Sometimes a person may have dark or bloody urine so small that it can only be detected using special medical tests.
Get FREE sample copy at:
The IgA Nephropathy (IgAN) market report also covers emerging drugs, current treatment practices, IgA Nephropathy (IgAN) market share of the individual therapies, current and forecasted IgA Nephropathy (IgAN) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current IgA Nephropathy (IgAN) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
IgA Nephropathy (IgAN) Market Key Facts
IgA nephropathy is more common in males than in females. Virtually all studies show a male predominance of at least 2:1, with reported ratios of up to 6:1. The higher male predilection is observed in white patients in northern Europe and the United States.
A systematic review of biopsy-based studies spanning multiple countries suggests an overall population incidence of at least 2.5 per 100,000. Only one study in this review was from Japan, and most were from Europe and North America. [Jennifer C. Rodrigues et. al., 2017]
Key Benefits of IgA Nephropathy (IgAN) Market Report
IgA Nephropathy (IgAN) market report provides an in-depth analysis of IgA Nephropathy (IgAN) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The IgA Nephropathy (IgAN) market report will help in developing business strategies by understanding the IgA Nephropathy (IgAN) Market trends & developments, key players and future market competition that will shape and drive the IgA Nephropathy (IgAN) market in the upcoming years.
The IgA Nephropathy (IgAN) market report covers IgA Nephropathy (IgAN) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the IgA Nephropathy (IgAN) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The IgA Nephropathy (IgAN) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted IgA Nephropathy (IgAN) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of IgA Nephropathy (IgAN) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
IgA Nephropathy (IgAN) Epidemiology
The IgA Nephropathy (IgAN) epidemiology section covers insights about historical and current IgA Nephropathy (IgAN) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
IgA Nephropathy (IgAN) Drugs Uptake and Key Market Players
The IgA Nephropathy (IgAN) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy (IgAN) market or expected to get launched in the market during the study period. The analysis covers IgA Nephropathy (IgAN) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The current pipeline for IgA Nephropathy has many significant products. The dynamics of IgA Nephropathy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also due to the expected launch of many therapies during the forecast period.
Some of the Key players involved in the development of therapies for the treatment of IgA Nephropathy includes:
and many others
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. IgA Nephropathy (IgAN) Competitive Intelligence Analysis
4. IgA Nephropathy (IgAN) Market Overview at a Glance
5. IgA Nephropathy (IgAN) Disease Background and Overview
6. IgA Nephropathy (IgAN) Patient Journey
7. IgA Nephropathy (IgAN) Epidemiology and Patient Population
8. IgA Nephropathy (IgAN) Treatment Algorithm, Current Treatment, and Medical Practices
9. IgA Nephropathy (IgAN) Unmet Needs
10. Key Endpoints of IgA Nephropathy (IgAN) Treatment
11. IgA Nephropathy (IgAN) Marketed Products
12. IgA Nephropathy (IgAN) Emerging Therapies
13. IgA Nephropathy (IgAN) Seven Major Market Analysis
14. Attribute Analysis
15. IgA Nephropathy (IgAN) Market Outlook (7 major markets)
16. IgA Nephropathy (IgAN) Access and Reimbursement Overview
17. KOL Views on the IgA Nephropathy (IgAN) Market.
18. IgA Nephropathy (IgAN) Market Drivers
19. IgA Nephropathy (IgAN) Market Barriers
21. DelveInsight Capabilities
DelveInsight’s IgA Nephropathy (IgAN) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of IgA Nephropathy (IgAN) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
IgA Nephropathy (IgAN) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the IgA Nephropathy (IgAN) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States